Brainstorm Cell Therapeutics Updates Fiscal Year End
Ticker: BCLI · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: fiscal-year-end, administrative
Related Tickers: BCLI
TL;DR
Brainstorm Cell Therapeutics (BCLI) just changed its fiscal year end to Dec 31. No big news, just admin.
AI Summary
On March 25, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing indicates a change in the company's fiscal year end to December 31st. This is a routine administrative update.
Why It Matters
This filing signals a change in the company's financial reporting calendar, which may affect the timing of future financial disclosures.
Risk Assessment
Risk Level: low — The filing is a routine administrative update regarding the company's fiscal year end and does not involve significant operational or financial changes.
Key Players & Entities
- Brainstorm Cell Therapeutics Inc. (company) — Registrant
- March 25, 2025 (date) — Date of earliest event reported
- December 31 (date) — New Fiscal Year End
- 1325 Avenue of Americas (address) — Company Business Address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a change in Brainstorm Cell Therapeutics Inc.'s fiscal year end to December 31.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on March 25, 2025.
What is the new fiscal year end for Brainstorm Cell Therapeutics Inc.?
The new fiscal year end for Brainstorm Cell Therapeutics Inc. is December 31.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
What is the company's business address?
The company's business address is 1325 Avenue of Americas, 28th Floor, New York, NY 10019.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding BRAINSTORM CELL THERAPEUTICS INC. (BCLI).